Update: Estrogen and estrogen plus progestin therapy in the care of women at and after the menopause

Women's Health

Volumn 8, Issue 2, 2012, Pages 169-189

  Davey, Dennis A ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

age; age at menopause; benefits; hormone; menopause; risks; therapy

Indexed keywords

CONJUGATED ESTROGEN; ESTROGEN; GESTAGEN; MEDROXYPROGESTERONE ACETATE; PLACEBO;

ALZHEIMER DISEASE; BODY MASS; BODY WEIGHT; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; CANCER SCREENING; CARDIOVASCULAR RISK; COLORECTAL CANCER; DISEASE ASSOCIATION; DRUG SAFETY; ENDOMETRIUM CARCINOMA; ESTROGEN THERAPY; HIP FRACTURE; HORMONE ACTION; HUMAN; ISCHEMIC HEART DISEASE; LUNG CANCER; MAMMOGRAPHY; MENOPAUSE; MORTALITY; OSTEOPOROSIS; OVARIECTOMY; OVARY CANCER; REVIEW; RISK BENEFIT ANALYSIS; TREATMENT DURATION; VENOUS THROMBOEMBOLISM; WOMEN'S HEALTH;

ADULT; AGED; BREAST NEOPLASMS; CORONARY DISEASE; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; MENOPAUSE; MIDDLE AGED; NEOPLASMS; PROGESTINS; RISK FACTORS; STROKE; VENOUS THROMBOEMBOLISM;

EID: 84858054447     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/whe.12.1     Document Type: Review

References (97)

1. Rossouw JE, Anderson GL, Prentice RL et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal result form the Women's Health Initiative randomised controlled trial. JAMA 288, 321-333 (2002). (Pubitemid 34761611)
2. Anderson GL, Limache M, Assaf AR et al. Women's Health Initiative Steering Committee: Effects of conjugated equine estrogens in postmenopausal women with hysterectomy: The Women's Health Initiative randomised controlled trial. JAMA 291, 1701-1712 (2004). (Pubitemid 38489892)
3. Santen RJ, Allred DC, Ardoin SP et al. Postmenopausal hormone therapy: An Endocrine Society scientific statement. J. Clin. Endocrinol. Metab. 95(7 Suppl1), S1-S66 (2010).
4. North American Menopause Society. Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 17, 242-255 (2010).
5. Sturdee DW, Pines A, Archer DF et al. On behalf of the International Menopause Society Writing Group. Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health. Climacteric 14, 302-320 (2011).
6. Beral V, Reeves G, Bull D et al. Million Women Study Collaborators. Breast cancer risk in relation to the interval between menopause and starting hormone therapy. J. Natl Cancer Inst. 103, 296-305 (2011).
7. Stram DO, Liu Y, Henderson KD et al Age-specific effects of hormone therapy use on mortality and ischemic heart disease mortality among women in the California Teachers Study Menopause 18, 253-261 (2011).
8. Hays J, Ockene JK, Brunner RL et al. Effects of estrogen plus progestin on health-related quality of life. N. Engl. J. Med. 348, 1839-1854 (2003). (Pubitemid 36532310)
9. Welton AJ, Vickers M, Kim J et al. Health related quality of life after combined hormone replacement therapy: Randomised controlled trial. BMJ 337, a1190 (2008).
10. Quinn SD, Domoney C. The effects of hormones on urinary incontinence in postmenopausal women. Climacteric 12, 106-113 (2009).
11. Robinson D, Cardozo L. Estrogens and the lower urinary tract. Neurourol. Urodyn. 30, 754-757 (2011).
12. Freeman EW, Sammel MD, Lin H et al. Duration of menopausal hot flushes and associated risk factors. Obstet. Gynecol. 117, 1095-1104 (2011).
13. Szmuilowicz ED, Manson JE, Rossouw JE et al. Vasomotor symptoms and cardiovascular events in postmenopausal women. Menopause 603-610 (2011).
14. Huang Y, Malone KE, Cushing-Haugen KL et al. Relationship between menopausal symptoms and risk of postmenopausal breast cancer. Cancer Epidemiol. Prev. 20, 379-388 (2011).
15. Tural A, Yodemir T, Erenus M. Assessment of bone mineral density should be considered earlier in perimenopausal women with vasomotor symptoms. Int. J. Gynaecol. Obstet. 107, 114-116 (2009).
16. Berry DA, Cronin KA, Pleveritis SK et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N. Engl. J. Med. 353, 1784-1792 (2005). (Pubitemid 41549890)
17. Coldlitz GA, Rosner B. Cumulative risk of breast cancer to age 70 years according to risk factor status: Data from Nurses' Health Study. Am. J. Epidemiol. 152, 950-964 (2000).
18. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 350, 1047-1059 (1997).
19. Million Women Study Collaborators. Breast cancer and hormone replacement therapy in the Million Women Study. Lancet 362, 419-427 (2003).
20. Nielsen M, Thomsen JL, Primadhl S, Dryeberg U, Andersen JA. Breast cancer and atypia among young and middle-aged women: A study of 110 medicolegal autopsies. Br. J. Cancer 56, 814-819 (1987). (Pubitemid 18048359)
21. Cauley JA, Lucas FL, Kuller LH, Stone K, Browner W, Cummings SR. Elevated serum estradiol and testosterone concentrations are associated with a high risk of breast cancer. Study of Osteoporotic Fractures Research Group. Ann. Intern. Med. 130(4 Pt 1), 270-277 (1999). (Pubitemid 29091854)
22. Kuhl H, Stevenson J. The effect of medroxyprogesterone acetate on estrogen-dependent risks and benefits - an attempt to interpret the Women's Health Initiative results. Gynecol. Endocrinol. 22, 303-317 (2006). (Pubitemid 43941407)
23. Becker S, Dossus L, Kaaks R. Obesity related hyperinsulinaemia and hyperglycaemia and cancer development. Arch. Physiol. Biochem. 115, 86-96 (2009).
24. Andersson B, Mattson LA, Hahn L et al. Estrogen replacement therapy decreases hyperandrogenicity and improves glucose homeostasis and plasma lipids in postmenopausal women with non-insulin dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 82, 638-643 (1997). (Pubitemid 27068643)
25. Heiss G, Wallace R, Anderson GL et al.; WHI Investigators. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA 299, 1036-1045 (2008). (Pubitemid 351347060)
26. LaCroix AZ, Chlebowski RT, Manson JE et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomised: A randomized controlled trial. JAMA 305, 1305-1314 (2011).
27. De Frank JT, Brewer NT. The background review for the USPSTF recommendation on screening for breast cancer. Ann. Intern. Med. 152, 537-538 (2010).
28. van Schoor G, Moss M, Otten JD et al. Increasingly strong reduction in breast cancer mortality due to screening. Br. J. Cancer 104, 910-914 (2011).
29. McTiernan A, Chlebnowski RT, Martin C et al. Conjugated equine estrogens influence on mammographic density in postmenopausal women in a substudy of the Women's Health Initiative randomized trial. J. Clin. Oncol. 27, 6135-6143 (2009).
30. McTiernan A, Martin CF, Peck JD et al. Estrogen-plus-progestin use and mammographic density in postmenopausal women. J. Natl Cancer Inst. 97, 1366-1376 (2009).
31. Chlebowski RT, Anderson G, Pettinger M et al. Estrogen plus progestin and breast cancer detection by means of mammography and breast biopsy. Arch. Intern. Med. 168, 370-377 (2008). (Pubitemid 351347128)
32. Buist DS. Anderson ML, Reed SD et al. Short-term therapy suspension and mammography recall: A randomized trial. Ann. Intern. Med. 150, 752-765 (2009
33. Kerlikowski K, Cook AJ, Buist DS et al. Breast cancer risk by breast density, menopause and postmenopausal hormone use. J. Clin. Oncol. 28, 3830-3837 (2010).
34. Stefanick ML, Anderson GL, Margolis KL et al. Effects of conjugated equine estrogens on breast cancer and mammography in postmenopausal women with hysterectomy. JAMA 295, 1647-1657 (2006).
35. Chlebowski RT, Anderson Gl, Gass M et al Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 304, 1684-1692 (2010).
36. Chlebowski RT, Anderson GL. The influence of time from menopause and mammography on hormone therapy-related cancer risk assessment. J. Natl Cancer Inst. 103, 284-285 (2011).
37. Prentice RL, Chlebowski RT, Stefanick ML et al. Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and observational study. Am. J. Epidemiol. 167, 1407-1415 (2008).
38. Jordan VC, Ford LG. Paradoxical effect of estrogen on breast cancer risk; a 'new' biology of estrogen induced apoptosis. Cancer Prev. Res. 4, 633-637 (2011).
39. Anderson GL, Chlebowski RT, Rossouw JE et al. Prior hormone therapy and breast cancer risk in Women's Health Initiative randomized trial of estrogen plus progestin. Maturitas 55, 103-115 (2006). (Pubitemid 44307491)
40. Prentice RL, Chlebowski RT, Stefanick ML et al. Estrogen plus progestin therapy and breast cancer in recently postmenopausal women. Am. J. Epidemiol. 167, 1207-1216 (2008). (Pubitemid 351670642)
41. Prentice RL, Manson JE, Lange RD et al. Benefits and risks of postmenopausal hormone therapy when it is initiated soon after the menopause. Am. J. Epidemiol. 170(1), 12-23 (2009).
42. LaCroix AZ Chlebowski RT, Manson JE et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: A randmoized controlled trial. JAMA 305, 1305-1314 (2011).
43. Lethaby A, Suckling J, Barlow D, Farquhar CM, Jepson RG, Roberts H. Hormone replacement therapy in postmenopausal women: Endometrial hyperplasia and irregular bleeding. Cochrane Database Syst. Rev. 3, CD000402 (2004).
44. Jaakkola S, Lyytinen H, Pukkala E, Ylokorkaka O. Endometrial cancer in postmenopausal women using estradiol-progestin therapy. Obstet. Gynecol. 114, 1197-1204 (2009).
45. Morch LS, Lokkegaard E, Andreasen AH, Kriger-Kjaer S, Lidegaard O. Hormone therapy and ovarian cancer. JAMA 302, 298-305 (2009).
46. Chute CG, Willett WC, Coldlitz GA, Stampfer MJ, Rosner B, Speizer FE. A prospective study of reproductive history and exogenous hormones on the risk of colorectal cancer in women. Epidemiology 2, 201-207 (1991).
47. Al-Azzawi F. Wahab M. Estrogen and colon cancer: Current issues. Climacteric 5, 3-14 (2002). (Pubitemid 34309851)
48. Chlebowski RT, Schwartz AG, Wakelee H et al. Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): A post-hoc analysis of a randomised trial. Lancet 374(9697), 1243-1251 (2009).
49. Cushman M, Kuller LH, Prentice R et al. Estrogen plus progestin and risk of venous thrombosis. JAMA 92, 1573-1580 (2004). (Pubitemid 39314963)
50. Sare GM, Gray LJ, Bath P. Association between hormone replacement therapy and subsequent arterial and venous vascular events: A meta-analysis. Eur. Heart J. 29, 2031-2041 (2008).
51. Canonico M, Plu-Bureau G, Lowe GD, Scarabin PY Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: Systematic review and meta-analysis. BMJ 336(7655), 1227-1231 (2008). (Pubitemid 351809317)
52. Canonico M, Oger E, Plu-Bureau G et al. Hormone therapy and venous thromboembolism among postmenopausal women impact of the route of estrogen administration and progestogens: The ESTHER study. Circulation 115, 840-845 (2007). (Pubitemid 46294724)
53. Wassertheil-Smoller S, Hendrix SL Limacher M et al. Effect of estrogen plus progestin on stroke in postmenopausal women: The Women's Health Initiative: A randomized trial. JAMA 289, 2673-2684 (2003). (Pubitemid 37430138)
54. Bath PM, Gray LJ. Association between hormone replacement therapy and subsequent stroke: A meta-analysis. BMJ 330(7487), 342 (2005).
55. Magliono DJ, Rogers SL. Abramson MJ, Tonkin AM. Hormone therapy and cardiovascular disease: A systematic review and meta-analysis. BJOG 113, 5-14 (2006).
56. Grodstein F, Manson JE, Stampfer MJ, Rexrode K. Postmenopausal hormone therapy and stroke: Role of time since menopause and age at initiation of hormone therapy. Arch. Intern. Med. 68, 861-866 (2008). (Pubitemid 351620088)
57. Renoux C, Dell'anielloa S, Garbe E, Suissa S. Transdermal and oral hormone therapy and the risk of stroke: A nested case-control study. BMJ 340, c2519 (2010).
58. Bush TL. Evidence for primary and secondary prevention of coronary artery disease in women taking oestrogen replacement therapy. Eur. Heart J. 17, 9-14 (1996). (Pubitemid 26278620)
59. Grodstein F, Stampfer MF, Coldlitz GA et al. Postmenopausal hormone therapy and mortality. N. Engl. J. Med. 336, 1769-1775 (1997).
60. Harman SM, Naftolin F, Brinton EA, Judelson DR. Is the estrogen controversy over? Deconstructing the Women's Health Initiative study: A critical evaluation of the evidence. Ann. NY Acad. Sci. 1052, 43-56 (2005). (Pubitemid 41338957)
61. Hulley S, Grady T, Bush T et al Randomized trial of estrogen plus progestin for the secondary prevention of coronary heart disease in postmenopausal women: Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 280, 605-613 (1998). (Pubitemid 28502636)
62. Rossouw JE, Prentice RL, Manson JE et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 297, 465-477 (2007).
63. Hsia J, Langer RD, Manson JE et al. Conjugated equine estrogens and coronary heart disease: The Women's Health Initiative. Arch. Intern. Med. 166(34), 357-365; Erratum in Arch. Intern. Med. 166, 759 (2006).
64. Grodstein F. Manson JE, Coldlitz GA, Willett WC, Speizer FE, Stampfer MJ. A prospective observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann. Intern. Med. 133, 993-941 (2000).
65. Grodstein F, Manson JE, Stampfer MJ. Hormone therapy and coronary heart disease: The role of time since menopause and age at hormone initiation. J. Women's Health 15, 35-44 (2006). (Pubitemid 43192860)
66. Salpeter SR, Walsh LM, Greyber E, Salpeter EE. Brief report: Coronary heart disease events associated with hormone therapy in younger and older women. A meta-analysis. J. Gen. Intern. Med. 21, 363-366 (2006).
67. Bray PF, Larson JC, Lacroix AZ et al. Usefulness of baseline lipids and C reactive protein in women receiving menopausal hormone therapy as predictors of treatment-related coronary events. Am. J. Med. 101, 599-605 (2008).
68. Herkert O, Kuhl H, Sandopw J, Busse R, Schini-Kerth VB. Sex steroids used in hormonal treatment increase vascular procoagulant activity by inducing thrombin receptor (PAR-1) expression: The role of the glucocorticoid receptor. Circulation 104, 2826-2831 (2001 (Pubitemid 33126658)
69. Williams JK, Hall J, Anthony MS, Register TC, Reiss SE, Clarkson TB. A comparison of tibolone and hormone replacement therapy on coronary artery and myocardial function in ovariectomized atherosclerotic monkeys. Menopause 41-51 (2002). (Pubitemid 34106163)
70. Oliver MF, Boyd GS. Effect of bilateral ovariectomy on coronary artery disease and serum lipids. Lancet 2(7105), 690-694 (1959).
71. Parker WH, Broder MS, Chang E et al. Ovarian conservation at the time of hysterectomy and long-term health outcomes in the Nurses Health Study. Obstet. Gynecol. 113, 1027-1037 (2009).
72. Ingelsson E, Lundholm C, Johansson AL, Altman D. Hysterectomy and risk of cardiovascular disease: A population-based cohort study. Eur. Heart J. 32, 45-50 (2011).
73. Brunk D. Menopause before age 46 doubles the CVD risk in later life. Women's Health News 13, 46 (2010).
74. Allison MA, Manson JE, Langer RD et al. Oophorectomy, hormone therapy, and subclinical coronary artery disease in women with hysterectomy: The Women's Health Initiative coronary artery calcium study. Menopause 14 (4 Pt 1), 639-647 (2008).
75. Al-Azzawi F, Palacios S. Hormonal changes during menopause. Maturitas 63, 135-137 (2009).
76. Calderon-Margalit R, Schwartz SM, Wellons MF et al. Prospective association of serum androgens and sex-hormone-binding globulin with subclinical cardiovascular disease in young adult women: The 'Coronary Artery Risk Development in Young Adults' women's study. J. Clin. Endocrinol. Metab. 95(4424), 31-71 (2010).
77. Psaty BM, Smith NL, Lemaitre RN et al Hormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal myocardial infarction in postmenopausal women. JAMA 285, 906-913 (2001). (Pubitemid 32171552)
78. Pradhan AD, Manson JE, Rossouw JE et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: Prospective analysis from the Women's Health Initiative bservational study. JAMA 288, 980-987 (2002). (Pubitemid 34920463)
79. Zanger D, Yang BK, Ardana J et al. Divergent effects of hormone therapy on serum markers of inflammation n post menopausal women with coronary disease on appropriate medical management. Am. Coll. Cardiol. 36, 1797-1802 (2000).
80. Corti R. Farouk ME, Badimon JJ. The vulnerable plaque and coronary syndrome. Am. J. Med. 113, 668-680 (2002).
81. Raggi P, Callister TQ, Cooil B et al. Identification of patients at increased risk of first unheralded acute myocardial infarction by electron-beam computed tomography. Circulation 101, 850-855 (2001 (Pubitemid 30117879)
82. Grodstein F, Clarkson TB, Manson JE. Understanding the divergent data on postmenopausal therapy. N. Engl. J. Med. 348, 645-650 (2003). (Pubitemid 36204960)
83. Post WS, Glodschmidt-Clermont PJ, Wilhide CC et al. Methylation of the estrogen receptor gene is associated with aging and atherosclerosis of the cardiovascular system. Cardiovasc. Res. 42, 985-991 (1999). (Pubitemid 29413198)
84. Villabanca AC, Jayachandran M, Banka C. Atherosclerosis and sex hormones: Current concepts. Clin. Sci. 119, 493-513 (2010).
85. Clarkson TB, Anthony MS, Morgan TM. Inhibition of postmenopausal atherosclerosis in progression: A comparison of the effects of conjugated equine estrogens and soy phytoestrogens. J. Clin. Endocrinol. Metab. 86, 412-417 (2001).
86. Williams JK, Anthony MS, Honore DE et al. Regression of atherosclerosis in female monkeys. Arterioscler. Thromb. Vasc. Biol. 15, 827-836 (1995).
87. Vrabli M, Fait T, Kovar J, Poledne R, Cesk R. Oral but not transdermal estrogen replacement therapy changes the composition of plasma lipoproteins. Metabolism 57, 1088-1092 (2008). (Pubitemid 351978068)
88. Gendersen K, Launer LJ, Dewey ME et al. Gender differences in the incidence of AD and vascular dementia: The EURODEM Studies. EURODEM Incidence Research Group. Neurology 53, 1992-1997 (1999).
89. Skoog I Gustafson D. HRT and dementia. J. Epidemiol. Biostat. 4, 227-251 (1999).
90. Shumaker SA Legault C, Rapp SR et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: The Women's Healh Initiative Memory Study: A randomised controlled trial. JAMA 289, 2651-2662 (2003). (Pubitemid 37430136)
91. Resnick SM, Makui PM, Rapp SR et al. Effects of combination estrogen plus progestin hormone treatment on cognition and affect. J. Clin.Endocrinol. Metab. 91, 1802-1810 (2006).
92. Espeland MA, Rapp SR, Shumaker SA et al. Conjugated equine estrogens and global cognitive function in postmenopausal women: Wmen's Health Initiative Memory Study. JAMA 291, 2959-2968 (2004). (Pubitemid 38802685)
93. Espeland MA, Tindle HA, Bushnell CA. Brain volumes, cognitive impairment and conjugated equine estrogens. J. Gerontol. A Bo. Sci. Med. Sci. 64, 1243-1250 (2009).
94. LeBlanc ES, Janowsky J, Chan BK, Nelson HD. Hormone replacement therapy and cognition: Systematic review and meta-analysis. JAMA 285, 1489-1499 (2011).
95. Henderson VW, Benke KS, Green RC, Cupples LA, Farrer LA, MIRAGE Study Group. Postmenopausal hormone therapy and Alzheimer's disease risk: Interaction with age. J. Neurol. Neurosurg. Psychiatry 76, 103-105 (2005). (Pubitemid 40013499)
96. Zandi PP, Carlson MC, Plassman BL et al. Hormone replacement therapy and incidence of Alzheimer's disease in older women: The Cache County Study. JAMA 288, 2123-2129 (2002). (Pubitemid 35265379)
97. Ryan J, Carriers I, Scali J et al. Characteristics of hormone therapy, cognitive function, and dementia; the prospective 3C study. Neurology 73, 1729-1737